[go: up one dir, main page]

BR9915132A - Method for inhibiting protein kinase activity, compounds of formula i and pharmaceutically acceptable salts thereof, use of the same, and pharmaceutical composition. - Google Patents

Method for inhibiting protein kinase activity, compounds of formula i and pharmaceutically acceptable salts thereof, use of the same, and pharmaceutical composition.

Info

Publication number
BR9915132A
BR9915132A BR9915132-4A BR9915132A BR9915132A BR 9915132 A BR9915132 A BR 9915132A BR 9915132 A BR9915132 A BR 9915132A BR 9915132 A BR9915132 A BR 9915132A
Authority
BR
Brazil
Prior art keywords
protein kinase
kinase activity
compounds
formula
pharmaceutically acceptable
Prior art date
Application number
BR9915132-4A
Other languages
Portuguese (pt)
Inventor
Kevin J Doyle
Paul Rafferty
Robert W Steele
David J Wilkins
Michael Hockley
Lee D Arnold
Anna M Ericsson
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9915132A publication Critical patent/BR9915132A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"MéTODO PARA INIBIR A ATIVIDADE DE QUINASE DE PROTEìNA, COMPOSTOS DA FóRMULA I E SAIS FARMACEUTICAMENTE ACEITáVEIS DOS MESMOS, USO DO MESMO, E, COMPOSIçãO FARMACêUTICA" A invenção refere-se a certos 3-aril ou 3-heteroaril pirazóis com fusão de anel 4,5(3,4)-bicíclico, que são inibidores da atividade de quinase de proteína, dos quais alguns são compostos novos, a composições farmacêuticas contendo estes pirazóis e a processos para preparar estes pirazóis."METHOD FOR INHIBITING THE PROTEIN KINASE ACTIVITY, FORMULA I COMPOUNDS AND PHARMACEUTICALLY ACCEPTABLE SALES, USE OF THE SAME, AND, PHARMACEUTICAL COMPOSITION" The invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4 pyrazoles. , 5 (3,4) -bicyclic, which are inhibitors of protein kinase activity, some of which are new compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.

BR9915132-4A 1998-11-06 1999-11-04 Method for inhibiting protein kinase activity, compounds of formula i and pharmaceutically acceptable salts thereof, use of the same, and pharmaceutical composition. BR9915132A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10746798P 1998-11-06 1998-11-06
PCT/US1999/026105 WO2000027822A2 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives

Publications (1)

Publication Number Publication Date
BR9915132A true BR9915132A (en) 2001-08-07

Family

ID=22316761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915132-4A BR9915132A (en) 1998-11-06 1999-11-04 Method for inhibiting protein kinase activity, compounds of formula i and pharmaceutically acceptable salts thereof, use of the same, and pharmaceutical composition.

Country Status (19)

Country Link
EP (1) EP1127051A2 (en)
JP (1) JP2003517447A (en)
KR (1) KR20010086005A (en)
CN (1) CN1335836A (en)
AU (1) AU762992B2 (en)
BG (1) BG105481A (en)
BR (1) BR9915132A (en)
CA (1) CA2350235A1 (en)
CZ (1) CZ20011563A3 (en)
HK (1) HK1042895A1 (en)
HU (1) HUP0200310A3 (en)
ID (1) ID30132A (en)
IL (1) IL142584A0 (en)
NO (1) NO20012219L (en)
PL (1) PL348210A1 (en)
SK (1) SK5282001A3 (en)
TR (1) TR200102277T2 (en)
WO (1) WO2000027822A2 (en)
ZA (1) ZA200103610B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
AU782353B2 (en) * 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
KR20020015034A (en) * 1999-04-06 2002-02-27 독터. 호르스트 하스칼, 잉에 린스 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
ATE349522T1 (en) 2000-04-05 2007-01-15 Zymogenetics Inc SOLUBLE CYTOKINE RECEPTOR ZALPHA11
MXPA03000458A (en) 2000-07-20 2004-06-02 Neurogen Corp Capsaicin receptor ligands.
MXPA03001452A (en) * 2000-08-18 2004-05-04 Agouron Pharma Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases.
CA2430376A1 (en) * 2000-12-08 2002-06-13 David J. Carini Semicarbazides and their uses as cyclin dependent kinase inhibitors
CA2461567C (en) 2001-09-19 2008-08-19 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
EP1444207A2 (en) 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
BR0307819A (en) * 2002-02-19 2005-04-26 Pharmacia Italia Spa Tricyclic pyrazole derivatives, process for preparing them as antitumor agents
CA2516254A1 (en) * 2003-02-17 2004-08-26 Pharmacia Italia S.P.A. Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7456169B2 (en) 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
WO2004080973A1 (en) * 2003-03-07 2004-09-23 Abbott Laboratories Fused tri and tetra-cyclic pyrazole kinase inhibitors
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
SG173222A1 (en) * 2003-04-07 2011-08-29 Agennix Usa Inc Aminoindeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases, useful for the treatment of alopecia, viral infections and hyperproliferative disorders, a pharmaceutical composition and uses related thereto
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
EP1740579B1 (en) 2004-03-24 2015-08-19 AbbVie Inc. Tricyclic pyrazole kinase inhibitors
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
DK2343304T3 (en) 2005-02-16 2015-06-29 Anacor Pharmaceuticals Inc BIOCIDE BORONOPHTHALIDE COMPOUNDS
WO2007120333A2 (en) * 2005-12-16 2007-10-25 Genentech, Inc. Tetracyclic kinase inhibitors
AU2006333527B2 (en) 2005-12-30 2013-08-01 Anacor Pharmaceuticals, Llc Boron-containing small molecules
RU2508113C2 (en) * 2006-02-16 2014-02-27 Анакор Фармасьютикалз, Инк. Boron-based small molecules as anti-inflammatory drugs
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
RU2547441C2 (en) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Boron-containing small molecules as anti-inflammatory agents
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
EP2597089A1 (en) * 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2011060199A1 (en) 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
ES2635333T3 (en) 2010-09-07 2017-10-03 Anacor Pharmaceuticals, Inc. Benzoxaborol derivatives to treat bacterial infections
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
CN102675326B (en) * 2012-04-26 2014-08-20 华东理工大学 Preparation method of 3,4-dihydrobenzene benzopyran [3,4-c] pyrazole tricyclic compound
WO2014039831A1 (en) * 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
ES2651367T3 (en) * 2013-07-15 2018-01-25 Basf Se Pesticide compounds
WO2016113261A1 (en) * 2015-01-13 2016-07-21 Basf Se Fused tricyclic compounds, compositions comprising these compounds and their use for con-trolling invertebrate pests
CN105884828A (en) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 Polycyclic compound, pharmaceutical composition and application thereof
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
BR112019010629B1 (en) 2016-11-28 2022-11-01 Sumitomo Chemical Company, Limited COMPOUND, METHOD FOR CONTROLLING A PEST, USE OF THE COMPOUND, AND COMPOSITION
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2021115560A1 (en) * 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
CN113773258B (en) * 2020-06-09 2023-08-25 兰州大学 Small molecule inhibitor of human LRRK2 protein and its application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
JPS60130521A (en) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk Anticancer agent
EP0866710A4 (en) * 1995-10-23 2001-07-11 Zymogenetics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DEFICITS
JP2001518502A (en) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト Indeno [1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activity
DK1023063T3 (en) * 1997-10-06 2004-01-26 Abbott Gmbh & Co Kg Indeno [1,2-c], naphtho [1,2-c] and benzo [6,7] cyclohepta [1,2-c] pyrazole derivatives

Also Published As

Publication number Publication date
AU762992B2 (en) 2003-07-10
HUP0200310A3 (en) 2002-12-28
BG105481A (en) 2001-12-29
NO20012219L (en) 2001-06-13
PL348210A1 (en) 2002-05-06
SK5282001A3 (en) 2002-01-07
IL142584A0 (en) 2002-03-10
KR20010086005A (en) 2001-09-07
WO2000027822A3 (en) 2000-08-10
AU1909100A (en) 2000-05-29
JP2003517447A (en) 2003-05-27
ZA200103610B (en) 2002-09-23
HK1042895A1 (en) 2002-08-30
WO2000027822A2 (en) 2000-05-18
ID30132A (en) 2001-11-08
CA2350235A1 (en) 2000-05-18
TR200102277T2 (en) 2002-01-21
NO20012219D0 (en) 2001-05-04
EP1127051A2 (en) 2001-08-29
CN1335836A (en) 2002-02-13
HUP0200310A2 (en) 2002-11-28
CZ20011563A3 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
BR9915132A (en) Method for inhibiting protein kinase activity, compounds of formula i and pharmaceutically acceptable salts thereof, use of the same, and pharmaceutical composition.
BR9911013A (en) Pyrazole derivatives as inhibitors of p-38 map kinase
BR0014225A (en) Pyrazole derivatives
BR0312464A (en) Tyrosine kinase inhibitors
DE69725608D1 (en) INDOLIN-2-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THE MEDICAMENT THEREOF
SK157899A3 (en) Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
BR9303993A (en) Compound, process for preparing the same and pharmaceutical composition
BR9812944A (en) Bicyclic kinase inhibitors
BRPI0215312B8 (en) compound, use of a compound, pharmaceutical composition, and process for preparing a compound
BR0210028A (en) Antibacterial agents
BR0007589A (en) Cell proliferation inhibitors
PT839041E (en) The invention relates to a process for preparing a medicament for the preparation of a medicament for the preparation of a medicament for the preparation of a medicament for the preparation of a medicament for the preparation of a medicament for the preparation of medicaments.
BR0008297A (en) Use of 4,6-o- (benzylidene-d1) -d-glucopyranose, 4,6-o-benzylidene-1-glucopyranose, and / or 4,6-o- (benzylidene-d1) -l-glucopyranose, or an acceptable pharmaceutical salt thereof, derived from benzaldehyde pharmaceutical composition, and process for the manufacture thereof
BR9809234A (en) Compound, pharmaceutical composition, use of a compound, processes to treat or prevent diseases of the endocrinological system, to manufacture a drug, to prepare a compound and a set, and use of it.
TR200000737T2 (en) Substituted chroma derivatives.
NO20014864L (en) Substituted 1,4-dihydroindeno [1,2-C] pyrazoles as inhibitors of tyrosine kinase
BR0214649A (en) Aminotetraline derivatives as muscarinic receptor antagonists
NO971997D0 (en) Use of immunomodulatory agents
BR9705456A (en) Heterocyclic compounds, aminomethyl process for their preparation and pharmaceutical compositions that contain them.
ES2192789T3 (en) HYDRAZON-BENZAZULEN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE COMPOUNDS.
UY26971A1 (en) NEW NEUROQUININE ANTAGONISTS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
DK0815109T3 (en) Process for the preparation of esters of anhydroecgonine

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH & CO. KG (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.